Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol
ABSTRACTNirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023. It aims to evaluate nirsevimab effectiveness against RSV-related hospitalizations lower respiratory tract infections (LRTI)...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Bog |
Udgivet: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Fag: | |
Online adgang: | Connect to this object online. |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
Internet
Connect to this object online.3rd Floor Main Library
Klassifikationsnummer: |
A1234.567 |
---|---|
Kopi 1 | Tilgængelig |